DIGITYPING Trademark

Trademark Overview

On Tuesday, January 30, 2018, a trademark application was filed for DIGITYPING with the United States Patent and Trademark Office. The USPTO has given the DIGITYPING trademark a serial number of 87776539. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, May 31, 2021. This trademark is owned by Transparency Life Sciences, Inc.. The DIGITYPING trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Scientific consulting services in the field of conducting clinical trials, and research and development of pharmaceuticals, biopharmaceuticals, and medical devices; clinical research for others in the fields of oncology, cardiology, virology, and infectious disease for the production of pharmaceuticals, biopharmaceuticals, and medical devices, and for the ultimate regulatory approval and registration of the foregoing goods; information technology consulting services relating to the collection, review, analysis and reporting of clinical trial and drug development information; pharmaceutical drug development services; pharmaceutical products development; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials
digityping

General Information

Serial Number87776539
Word MarkDIGITYPING
Filing DateTuesday, January 30, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, May 31, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 3, 2020

Trademark Statements

Goods and ServicesScientific consulting services in the field of conducting clinical trials, and research and development of pharmaceuticals, biopharmaceuticals, and medical devices; clinical research for others in the fields of oncology, cardiology, virology, and infectious disease for the production of pharmaceuticals, biopharmaceuticals, and medical devices, and for the ultimate regulatory approval and registration of the foregoing goods; information technology consulting services relating to the collection, review, analysis and reporting of clinical trial and drug development information; pharmaceutical drug development services; pharmaceutical products development; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, February 9, 2018
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameTransparency Life Sciences, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10001
Party NameTransparency Life Sciences, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10001

Trademark Events

Event DateEvent Description
Tuesday, June 1, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, May 31, 2021ABANDONMENT - NO USE STATEMENT FILED
Friday, October 30, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 28, 2020EXTENSION 1 GRANTED
Wednesday, October 28, 2020EXTENSION 1 FILED
Wednesday, October 28, 2020TEAS EXTENSION RECEIVED
Tuesday, April 28, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 3, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 3, 2020PUBLISHED FOR OPPOSITION
Wednesday, February 12, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, January 27, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, January 10, 2020EXAMINER'S AMENDMENT ENTERED
Friday, January 10, 2020NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, January 10, 2020EXAMINERS AMENDMENT E-MAILED
Friday, January 10, 2020EXAMINERS AMENDMENT -WRITTEN
Friday, June 28, 2019NOTIFICATION OF FINAL REFUSAL EMAILED
Friday, June 28, 2019FINAL REFUSAL E-MAILED
Friday, June 28, 2019FINAL REFUSAL WRITTEN
Tuesday, June 4, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, June 4, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, June 3, 2019ASSIGNED TO LIE
Tuesday, May 28, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, April 24, 2019APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, April 24, 2019TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, December 14, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, December 14, 2018NON-FINAL ACTION E-MAILED
Friday, December 14, 2018NON-FINAL ACTION WRITTEN
Tuesday, November 20, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, November 19, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, November 19, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, May 17, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, May 17, 2018NON-FINAL ACTION E-MAILED
Thursday, May 17, 2018NON-FINAL ACTION WRITTEN
Friday, May 11, 2018ASSIGNED TO EXAMINER
Friday, February 9, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM

Related Keywords

digityping development research clinical pharmaceutical pharmaceuticals information services medical drug scientific